Handelsavisen
prelaunch
Companies Healthcare 491000.KQ
49
491000.KQ KOSDAQ Medical Equipment, Supplies & Distribution

LivsMed Inc

$72 800,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
-44,2 %
ROE
-12,7 %
Net margin
-44,7 %
Debt / equity
0,06
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

LivsMed Inc is a South Korean medical equipment and supplies company that provides healthcare services and equipment to hospitals, clinics, and other healthcare facilities.

Business. LivsMed Inc is a healthcare company engaged in the medical equipment, supplies, and distribution industry. The firm operates within the Healthcare Services & Equipment sector, focusing on product sales. LivsMed Inc is headquartered in South Korea and is primarily listed on the KOSDAQ exchange under the ticker symbol 491000.KQ. Specific details regarding operating segments and geographic revenue mix are not disclosed.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
ActivityHealthcare Services & Equipment
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target140 000,00

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
140 000,00
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
-12,7 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 491000.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 491000.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    LivsMed Inc is a healthcare company engaged in the medical equipment, supplies, and distribution industry. The firm operates within the Healthcare Services & Equipment sector, focusing on product sales. LivsMed Inc is headquartered in South Korea and is primarily listed on the KOSDAQ exchange under the ticker symbol 491000.KQ. Specific details regarding operating segments and geographic revenue mix are not disclosed.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryMedical Equipment, Supplies & Distribution
    ActivityHealthcare Services & Equipment
    AI synthesis
    GENERATED

    LivsMed Inc has a highly liquid capital structure, with cash and equivalents of KRW 11.4 billion and a current ratio of 12.68, indicating strong short-term liquidity. However, the company has a negative net cash position after subtracting total debt, which is a key liquidity flag. The debt-to-equity ratio is low at 0.06, suggesting minimal leverage risk.

    The company's profitability metrics are negative, with a return on equity of -12.65% and a return on assets of -11.33%, indicating significant underperformance relative to industry norms. The operating loss of KRW 2.26 billion and net loss of KRW 2.29 billion highlight the company's current financial distress. These results are far below the industry median for profitability metrics, suggesting operational inefficiencies or pricing pressures.

    LivsMed Inc's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of diversification increases exposure to sector-specific risks and limits growth opportunities.

    The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the data. The operating cash flow is negative at KRW 34.74 billion, and free cash flow is also negative at KRW 27.86 billion, indicating a lack of cash generation to support growth initiatives. Capital expenditures of KRW 7.72 billion suggest some investment in infrastructure, but the scale is insufficient to offset the operating losses.

    The risk assessment indicates medium liquidity risk and low dilution risk. The negative net cash position is a key liquidity concern, but the low debt-to-equity ratio and high cash reserves mitigate some of the risk. No significant dilution sources are identified in the data, and the dilution potential is assessed as low.

    Recent investor relations data shows a mean price target of KRW 140,000, with a median and high price target also at KRW 140,000. The mean recommendation is 2.00, indicating a "buy" rating, with one analyst issuing a "buy" recommendation and no strong buy or hold ratings. This suggests limited analyst confidence in the company's near-term prospects.

    Key takeaways
    • LivsMed Inc has strong liquidity but is currently unprofitable with significant operating and net losses.
    • The company's capital structure is highly liquid, with a low debt-to-equity ratio and high cash reserves.
    • Profitability metrics are far below industry norms, indicating operational challenges.
    • The company's revenue is concentrated in a single segment, increasing exposure to sector-specific risks.
    • Analysts have issued a "buy" rating, but with limited consensus and no strong buy recommendations.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $72 800,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $180.87B
    Net cash
    -$205.2M
    Current ratio
    12.7
    Debt / equity
    0.1
    ROA
    -11.3%
    ROE
    -12.7%
    Cash conversion
    152.0%
    CapEx / revenue
    -15.1%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price target$120 000,00 · Median $120 000,00
    Low $120 000,00High $120 000,00
    Operating income · consensus-28,5B KRW

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$140 000,00
    Mean$140 000,00
    Median$140 000,00
    High$140 000,00
    Spot$72 800,00
    +92.3 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-44,2 %Bottom quartile
    Net Margin-44,7 %Bottom quartile
    ROE-12,7 %Bottom quartile
    Capex / Rev-15,1 %Bottom quartile
    D/E0,06Above median
    Cash Conv1,52Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • LivsMed Inc Market data — financials · 2026-05-26
    • LivsMed Inc Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    491000.KQCanonical
    KOSDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage